Can I Take Alpha-Lipoic Acid with Cialis (Tadalafil)?

What Is Alpha-Lipoic Acid and Why Do Men on Tadalafil Take It?

Alpha-lipoic acid is a naturally occurring dithiol compound synthesized in small amounts by the human body and found in foods such as spinach, broccoli, and organ meats. As a dietary supplement, ALA is sold in doses ranging from 100 mg to 1,200 mg per day. Its proposed benefits include antioxidant activity, improved insulin sensitivity, and peripheral nerve support, which is why it appears frequently in men who also use tadalafil.

Men prescribed tadalafil often carry comorbidities. Erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) share overlapping metabolic risk factors with type 2 diabetes and diabetic peripheral neuropathy. A 2019 cross-sectional analysis published in the Journal of Sexual Medicine reported that roughly 35% of men seeking ED treatment had concurrent insulin resistance or frank type 2 diabetes. ALA's reputation for supporting nerve health and glycemic control makes it a popular add-on in exactly this population.

How ALA Works at the Cellular Level

ALA functions as a cofactor for mitochondrial enzymes including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. Both its oxidized (lipoic acid) and reduced (dihydrolipoic acid, DHLA) forms scavenge reactive oxygen species. In muscle and adipose tissue, ALA activates AMP-activated protein kinase (AMPK), increasing GLUT-4 translocation to the cell surface and thereby enhancing glucose uptake independent of insulin. This AMPK-mediated pathway is central to the hypoglycemic concern discussed below [1].

How Tadalafil Works

Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP (cGMP) in smooth muscle. By prolonging cGMP signaling, tadalafil relaxes smooth muscle in penile corpora cavernosa (enabling erection), in the bladder neck and prostate (relieving BPH symptoms), and in pulmonary vasculature (approved for pulmonary arterial hypertension as Adcirca). Smooth muscle relaxation also causes mild systemic vasodilation and a modest reduction in systemic blood pressure. The FDA-approved prescribing information for tadalafil documents mean maximum decreases of 1.6 mmHg systolic and 0.8 mmHg diastolic compared with placebo in normotensive subjects [2].

The Primary Interaction: Blood-Pressure and Glucose Effects

The most clinically relevant concern pairing ALA with tadalafil is not a pharmacokinetic clash. The two drugs do not share the same metabolic enzyme to any meaningful degree, so one is not expected to raise or lower the blood level of the other. The interaction is pharmacodynamic: two agents with overlapping downstream effects on vascular tone and glucose handling acting at the same time.

ALA's Blood-Glucose Lowering Effect

Multiple controlled trials have examined ALA's glycemic impact. A systematic review and meta-analysis by Akbari et al. (2018), which pooled 23 randomized controlled trials (N=1,532), found that ALA supplementation significantly reduced fasting blood glucose by a mean of 2.29 mg/dL and HbA1c by 0.24 percentage points compared with placebo [3]. Those numbers sound modest in isolation. In a man with pre-diabetes whose fasting glucose is already sitting near 100 mg/dL, however, even small downward shifts in glucose can produce symptoms of lightheadedness if they coincide with the vasodilatory peak of a tadalafil dose.

Tadalafil's Vasodilatory Contribution

Tadalafil reaches peak plasma concentration (Tmax) approximately 2 hours after an oral dose and has a half-life of approximately 17.5 hours [2]. For men taking the 5 mg daily formulation, there is no single sharp peak; plasma levels plateau at steady state. For on-demand dosing (10 mg or 20 mg), the 2-hour window around dosing is when vasodilatory effects are most pronounced. If a man takes 600 mg ALA simultaneously with 20 mg tadalafil on an empty stomach, both the glucose-lowering and the vasodilatory effects may peak together, potentially causing symptomatic hypotension or dizziness, particularly in men who are also taking antihypertensives.

Who Is Most at Risk

The men most likely to experience a clinically noticeable interaction are those who:

• Have diabetes or pre-diabetes and are using ALA specifically to improve glycemic control
• Take tadalafil on-demand at higher doses (10 to 20 mg) rather than the daily 5 mg regimen
• Also use alpha-blockers such as tamsulosin (Flomax) for BPH, a combination the FDA prescribing information already flags for additive hypotension [2]
• Are fasting or skipping meals around the time of dosing

Men with normal glucose metabolism and stable blood pressure taking low-dose daily tadalafil are at low risk. A symptom they should watch for regardless of risk level is lightheadedness upon standing, which may indicate orthostatic hypotension from combined vasodilation and mild glucose lowering.

The Secondary Interaction: Thyroid Hormone Conversion

A less commonly discussed concern is ALA's potential effect on thyroid hormone metabolism. Animal studies and limited human data suggest that pharmacological doses of ALA (above 600 mg/day) may inhibit the deiodinase enzymes that convert thyroxine (T4) to the active hormone triiodothyronine (T3). One rodent study by Schupke et al. Documented a dose-dependent reduction in serum T3 with high-dose lipoic acid supplementation, though direct human RCT evidence remains limited [4].

Why This Matters for Tadalafil Users

Tadalafil itself does not directly affect thyroid function. The relevance here is indirect. Men taking tadalafil for ED may also have undiagnosed or managed hypothyroidism, since thyroid dysfunction is a recognized contributor to sexual dysfunction. If high-dose ALA is suppressing T3 levels, it could worsen the underlying condition tadalafil is treating, reducing its clinical effectiveness. Men taking thyroid replacement therapy such as levothyroxine alongside tadalafil and ALA should have their TSH and free T3 rechecked 6 to 8 weeks after starting ALA if doses exceed 600 mg/day.

The Biotin Interference Issue

A separate thyroid-related caution: high-dose biotin, often co-formulated with ALA in "metabolic support" supplements, can falsely raise free T4 and suppress TSH on immunoassay-based lab panels. This is a laboratory artifact, not a true hormone change, but it can produce confusing thyroid results. The FDA issued a safety communication on biotin-interference with lab tests in 2017 [5]. Men on combined ALA-biotin products should inform their lab or clinician so samples can be collected before the morning biotin dose.

Pharmacokinetic Profile: Do ALA and Tadalafil Compete for the Same Enzymes?

Understanding enzyme-level interactions requires looking at each agent's metabolic pathway.

Tadalafil's CYP3A4 Metabolism

Tadalafil is metabolized primarily by CYP3A4 in the liver. Potent CYP3A4 inhibitors such as ketoconazole or ritonavir meaningfully raise tadalafil plasma exposure and are subject to dose adjustment warnings in the prescribing information [2]. CYP3A4 inducers such as rifampicin can reduce tadalafil AUC by up to 88%.

ALA and CYP Enzymes

Alpha-lipoic acid is not a well-characterized CYP3A4 inhibitor or inducer at typical supplemental doses (300 to 600 mg/day). In vitro data from enzyme kinetic studies suggest that lipoic acid has only weak affinity for CYP3A4 at concentrations achievable through oral supplementation [6]. Based on currently available data, ALA at standard doses is not expected to alter tadalafil plasma concentrations to a clinically significant degree.

At very high doses (above 1,200 mg/day, a range used in some neuropathy treatment protocols), the data are more limited. Caution is reasonable at such doses until dedicated human pharmacokinetic studies are conducted.

Protein Binding

Tadalafil is approximately 94% bound to plasma proteins. ALA, given its rapid reduction and conjugation after absorption, does not appear to compete for the same albumin binding sites. No published studies have identified displacement interactions between these two compounds.

Dosing, Timing, and Practical Safety Guidance

Most men who are taking both ALA and tadalafil can do so safely by applying a few straightforward principles.

Recommended Approach for Most Men

1. Take ALA with food. Oral ALA absorption is faster on an empty stomach, which also amplifies transient glucose-lowering. Taking it with a meal blunts the glucose dip and reduces lightheadedness risk. A 2012 pharmacokinetic study in healthy volunteers found that co-administration with a standardized meal reduced peak ALA plasma concentration by approximately 30% while leaving total exposure (AUC) largely unchanged [7].
2. Start ALA at a low dose (300 mg/day) and titrate. This lets you assess tolerability before reaching the doses where glucose and thyroid effects become more pronounced.
3. Use the 5 mg daily tadalafil regimen if medically appropriate. Daily low-dose tadalafil avoids the sharp plasma peaks of on-demand dosing and produces more stable, lower-magnitude hemodynamic effects. A 2014 Cochrane review of daily vs. On-demand tadalafil (15 RCTs, N=2,740) found no significant difference in ED outcomes but noted that daily dosing produced more predictable tolerability [8].
4. Monitor blood pressure if you also take alpha-blockers. Men on tamsulosin or alfuzosin should take tadalafil at a minimum of 4 hours after the alpha-blocker, per FDA prescribing guidance, and should note that adding ALA may slightly augment this caution.

Who Should Consult a Physician Before Combining

Men in the following categories should speak with their prescribing physician or pharmacist before adding ALA to a tadalafil regimen:

• Diagnosed type 1 or type 2 diabetes using insulin or sulfonylureas (combined glucose-lowering effects could produce symptomatic hypoglycemia)
• Active or treated hypothyroidism on levothyroxine
• Taking nitrates for cardiovascular disease (tadalafil is already absolutely contraindicated with nitrates; adding ALA does not change this contraindication but clarifies the conversation needed)
• Planning to use ALA doses above 600 mg/day for neuropathy treatment

The American Diabetes Association's 2024 Standards of Care note that "clinicians should discuss over-the-counter supplements with patients at every visit, as interactions with prescribed glucose-lowering agents are underreported" [9].

Evidence Quality and Limitations

Most evidence on ALA-tadalafil interactions is indirect. No published randomized controlled trial has prospectively studied this specific combination. The concerns outlined here are constructed from:

• Human pharmacokinetic data for each agent individually
• The mechanistic literature on ALA's AMPK activation and glucose-lowering
• Case series and observational data in diabetic men using PDE5 inhibitors
• Extrapolation from animal data on thyroid deiodinase inhibition

This evidence base is credible but incomplete. The absence of a documented serious interaction in the published literature is reassuring, but it may also reflect underreporting rather than genuine safety.

The Natural Medicines Database, used by pharmacists and clinicians as a reference for supplement interactions, rates the ALA-tadalafil combination as a "minor" interaction, primarily citing the glucose-lowering overlap [10]. Mayo Clinic's drug-interaction tool gives no contraindication but flags monitoring for hypoglycemic symptoms.

Monitoring Parameters If You Are Already Taking Both

If you are already taking both ALA and tadalafil, the following monitoring plan covers the major risk areas:

Immediately actionable:

• Check fasting blood glucose at baseline and at 4 weeks if you have any history of impaired fasting glucose
• Note any dizziness or lightheadedness within 2 hours of dosing either agent

At 6 to 8 weeks if ALA dose is above 600 mg/day:

• TSH and free T3 (to detect early signs of T3 suppression)
• Report results to the clinician managing your tadalafil prescription

Ongoing:

• Blood pressure at routine visits, with specific mention of both agents in the medication list
• Review any "metabolic support" or "antioxidant" combination products for co-formulated biotin above 5 mg/day before lab draws

The Endocrine Society's clinical practice guidelines on male hypogonadism and sexual dysfunction (2018) state that "a complete medication and supplement history is essential before initiating or adjusting PDE5 inhibitor therapy, as over-the-counter agents can modify both efficacy and safety profiles" [11].

ALA and Erectile Function: Is There a Direct Benefit?

One question that naturally follows is whether ALA may actually support erectile function directly. The answer is: it might, through antioxidant and vascular mechanisms, but the clinical evidence in humans is limited.

Oxidative Stress and Erectile Dysfunction

Endothelial dysfunction driven by oxidative stress is a key pathway in vasculogenic ED. ALA's ability to regenerate glutathione and vitamins C and E, and to quench superoxide directly via DHLA, theoretically supports endothelial nitric oxide (NO) bioavailability. NO is the same upstream signal that eventually produces the cGMP tadalafil acts to preserve.

A small randomized trial by Filippi et al. (2009, N=50) in men with type 2 diabetes and ED tested the combination of tadalafil 20 mg plus 600 mg ALA twice daily against tadalafil alone over 24 weeks. The combination group showed statistically greater improvement in International Index of Erectile Function (IIEF-5) scores at 24 weeks (mean improvement 7.1 vs. 4.3 points, P<0.05) [12]. This is a single small trial and should not be over-interpreted, but it does suggest the combination may offer additive benefit rather than harm in the specific context of diabetic ED.

Neuropathic ED and ALA

ALA is used clinically at 600 mg/day (and intravenously at 600 mg/day for 3 weeks in the ALADIN trials) for diabetic peripheral neuropathy. Since cavernous nerve impairment contributes to ED in diabetic men, ALA's neuroprotective effect may restore nerve-mediated erection independently of the vascular pathway tadalafil targets. The ALADIN III trial (N=509) showed that 600 mg/day oral ALA over 24 weeks produced statistically significant improvement in Total Symptom Score for neuropathy vs. Placebo [13], though ED-specific outcomes were not a primary endpoint.

Special Populations

Men With Type 2 Diabetes

This group sits at the crossroads of most risk factors discussed above: they are likely to be on antihypertensives, may already have a degree of orthostatic blood pressure instability, often use ALA for neuropathy, and are disproportionately represented in the ED population. For them, the Filippi trial data [12] are the most directly relevant evidence. The glucose-lowering interaction requires active monitoring, particularly if they use insulin or sulfonylureas alongside ALA.

Men on Daily Low-Dose Tadalafil for BPH

The 5 mg once-daily tadalafil indication for BPH is FDA-approved and produces steady-state plasma levels without sharp peaks. ALA added to this regimen is less likely to produce symptomatic hypotension than the on-demand 20 mg dose scenario, because the hemodynamic effects are distributed throughout the day. Still, men with BPH are on average older and more likely to carry cardiovascular comorbidities that heighten sensitivity to even modest blood-pressure changes.

Men With Pulmonary Arterial Hypertension on Tadalafil (Adcirca)

Tadalafil 40 mg daily (Adcirca) is used for pulmonary arterial hypertension. At this dose, systemic vasodilation is more pronounced. Adding ALA for any reason in this population requires cardiology review, since even minor additive reductions in systemic vascular resistance could be clinically significant.